Clinical trials: Adrenal Cortical Cancer
Hyperaldosteronism
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.
Rationale: Primary hyperaldosteronism (PA) is the most frequent form of secondary hypertension. In PA autonomous hypersecretion of aldosterone by one or both adrenal glands causes hypertension that is often refractory to…
- Trial name
- SPARTACUS (NCT01096654)
- Testing
- Ct-scan or adrenal vein sampling
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Radboud University Medical Center
Hyperaldosteronism
Adrenal Vein Sampling International Study (AVIS Study)
The AVIS Study is a retrospective multicenter international study that aims to answer a series of questions on the use and performance of adrenal venous catheterization (AVS) for the diagnosis of primary hyperaldosteronism…
- Trial name
- AVIS (NCT01234220)
- Where
- 20 sites in United States, Australia and 8 more
- Volunteers
- 2,604 people
- Sponsor
- University Hospital Padova
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy Trial Type : Single arm, prospective trial Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib) Treatment…
- Trial name
- ACCOMPLISH (NCT05036434)
- Testing
- Pembrolizumab / Lenvatinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Adrenocortical Tumor
International Pediatric Adrenocortical Tumor Registry
This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological…
- Trial name
- NCT00700414
- Where
- 5 sites in United States
- Volunteers
- 9,999 people
- Sponsor
- St. Jude Children's Research Hospital
Renal Cell Carcinoma, Adrenal Carcinoma
VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma
Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism.
- Trial name
- NCT04666220
- Testing
- VETC evaluation
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Humanitas Clinical and Research Center
Adrenocortical Carcinoma
Phase 1 Study of 68Ga-R8760
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
- Trial name
- NCT05999292
- Testing
- 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radionetics Oncology
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Gland Neoplasms
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two rare cancer entities with a very unfavorable prognosis.
- Trial name
- COMETETACTIC (NCT02672020)
- Testing
- omics identity card
- Where
- 21 sites in France
- Volunteers
- 448 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia
First-in-human Evaluation of [18F]CETO
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia, Adrenal Cushing Syndrome, Non-Secretory Adrenal Adenoma
- Trial name
- NCT05361083
- Testing
- F18CETO
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Adrenal Tumor, Primary Aldosteronism
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be…
- Conditions
- Adrenal Tumor, Primary Aldosteronism, Cushing Syndrome, Pheochromocytoma
- Trial name
- NCT06229405
- Where
- South Korea
- Volunteers
- 8,200 people
- Sponsor
- Seoul National University Hospital
Adrenal Cortex Neoplasms
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
Background: Adrenocortical carcinoma is an aggressive cancer that starts in the adrenal gland at the top of the kidneys. It has a low survival rate if standard treatment options are not effective.
- Trial name
- NCT01255137
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Primary Aldosteronism, Secondary Hypertension
PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA).
- Conditions
- Primary Aldosteronism, Secondary Hypertension, Aldosterone-Producing Adenoma, Idiopathic Hyperaldosteronism
- Trial name
- NCT07027254
- Testing
- 68Ga-pentixafor PET/CT
- Where
- 2 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Adrenocortical Carcinoma
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months.
- Trial name
- NCT04358107
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie